Gossamer Bio/GOSS

$0.90

-7.47%
-
1D1W1MYTD1YMAX

About Gossamer Bio

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Ticker

GOSS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Faheem Hasnain

Employees

135

Headquarters

San diego, United States

Gossamer Bio Metrics

BasicAdvanced
$218.25M
Market cap
-
P/E ratio
-$1.38
EPS
1.76
Beta
-
Dividend rate
$218.25M
1.76095
$1.88
$0.45
1.25M
5.941
314.494
332.996
-15.09%
-61.54%
-480.5%
-74.38%
3.474
3.477
49.49%

What the Analysts think about Gossamer Bio

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 8 analysts.
535.56% upside
High $15.00
Low $0.50
$0.90
Current price
$5.72
Average price target

Gossamer Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-48.1M
20.25%
Profit margin
0%
-

Gossamer Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1.02%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.52
-$0.45
-$0.21
-$0.21
-
Expected
-$0.53
-$0.49
-$0.26
-$0.21
-$0.19
Surprise
-1.81%
-7.98%
-17.84%
1.02%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Gossamer Bio stock?

Gossamer Bio (GOSS) has a market cap of $218.25M as of April 13, 2024.

What is the P/E ratio for Gossamer Bio stock?

The price to earnings (P/E) ratio for Gossamer Bio (GOSS) stock is 0 as of April 13, 2024.

Does Gossamer Bio stock pay dividends?

No, Gossamer Bio (GOSS) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Gossamer Bio dividend payment date?

Gossamer Bio (GOSS) stock does not pay dividends to its shareholders.

What is the beta indicator for Gossamer Bio?

Gossamer Bio (GOSS) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Gossamer Bio stock price target?

The target price for Gossamer Bio (GOSS) stock is $5.72, which is 535.56% above the current price of $0.9. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Gossamer Bio stock

Buy or sell Gossamer Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing